Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.7 (CiteScore Tracker 3.3)
Index Copernicus  – 161.11; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 1, January-February, p. 39–43

doi: 10.17219/acem/33116

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

The effect of proton pump inhibitors on the gastric mucosal microenvironment

Yen-Chun Peng1,2,3,A,B,C,D,E,F, Lan-Ru Huang4,A,C,E, Hui-Ching Ho5,C, Chi-Sen Chang4,C,E, Shou-Wu Lee1,E, Ching-Chang Cheng6,E, May-Ching Wen7,C, Hong-Zen Yeh1,E, Shu-Peng Ho2,A,E,F

1 Division of Gastroenterology, Department of Internal Medicine,Taichung Veterans General Hospital, Taichung, Taiwan

2 Department of Veterinary Medicine, School of Medicine, National Chung Hsing University, Taichung, Taiwan

3 National Yang Ming University, Taipei, Taiwan

4 Department of Medical Laboratory Science and Biotechnology, Central Taiwan University of Science and Technology, Taichung, Taiwan

5 Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan

6 Laboratory Animal Service Center, Office of Research and Development, China Medical University, Taichung, Taiwan

7 Department of Pathology, Taichung Veterans General Hospital, Taichung, Taiwan

Abstract

Background. Proton pump inhibitors (PPIs) are widely applied for acid related disorders, and possess pleiotropic biological functions. The effect of PPIs on the gastric mucosa, neutrophil and Helicobacter pylori (H. pylori) infiltration and glandular atrophy has not been well investigated, particularly the duration of the effects of PPIs.
Objectives. To investigate the effects of PPIs on neutrophil infiltration, H. pylori infiltration and the gastric mucosa.
Material and Methods. A total of 76 adult patients with gastrointestinal symptoms who had undergone upper gastrointestinal endoscopy were enrolled in the study. Each patient’s history was recorded, including smoking, alcohol consumption and the duration of PPI use prior to gastric biopsy. Endoscopic biopsies of gastric antral mucosa were performed and evaluated by histology. Neutrophil and H. pylori infiltration were graded by H & E staining in accordance with the updated Sydney system.
Results. Among the 76 patients, 44 patients had H. pylori infection and 19 patients had taken PPIs for varying durations prior to gastric biopsy. Neutrophil infiltration was significantly inhibited by PPIs (p = 0.005). The duration of PPI use was correlated with inhibition of neutrophil and H. pylori infiltration. A logistical regression analysis demonstrated that PPIs significantly inhibited neutrophil infiltration in the gastric mucosa and were associated with atrophy of the mucosa.
Conclusion. PPIs attenuated neutrophil infiltration of gastric mucosa, and may be related to atrophy of the mucosa.

Key words

Helicobacter pylori, gastric mucosa, proton pump inhibitor, neutrophil

References (19)

  1. Yang YX, Metz DC. Safety of Proton Pump Inhibitor Exposure. Gastroenterology. 2010;139:1115–1127.
  2. Suzuki M, Suzuki H, Kitahora T, et al. Proton pump inhibitor modifies inflammatory reaction in human gastric mucosa infected by Helicobac-ter pylori. Aliment Pharmacol Ther. 2002;16(Suppl 2):229–234.
  3. Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxbock F, Graninger W. Omeprazole treatment diminishes intra- and extracellu-lar neutrophil reactive oxygen production and bactericidal activity. Crit Care Med. 2002;30:1118–1122.
  4. Handa O, Yoshida N, Fujita N, et al. Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors. Inflammation Research. 2006;55:476–480.
  5. Sadik CD, Kim ND, Luster AD. Neutrophils cascading their way to inflammation. Trends Immunol. 2011;32:452–460.
  6. Kozol R, Kopatsis A, Fligiel SE, Czanko R, Callewaert D. Neutrophil-mediated injury to gastric mucosal surface cells. Dig Dis Sci. 1994;39:138–144.
  7. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347:1175–1186.
  8. Yoshikawa T, Naito Y. The role of neutrophils and inflammation in gastric mucosal injury. Free Radic Res. 2000;33:785–794.
  9. Agastya G, West BC, Callahan JM. Omeprazole inhibits phagocytosis and acidification of phagolysosomes of normal human neutrophils in vitro. Immunopharmacol Immunotoxicol. 2000;22:357–372.
  10. Suzuki M, Mori M, Miura S, et al. Omeprazole attenuates oxygen-derived free radical production from human neutrophils. Free Radic Biol Med. 1996;21:727–731.
  11. Scaringi L, Cornacchione P, Fettucciari K, et al. Activity inhibition of cytolytic lymphocytes by omeprazole. Scand J Immunol. 1996;44:204–214.
  12. Wandall JH. Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. Gut. 1992;33:617–621.
  13. Yoshida N, Yoshikawa T, Tanaka Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors – inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther. 2000;14 Suppl 1:74–81.
  14. Kuipers EJ. Proton pump inhibitors and gastric neoplasia. Gut. 2006;55:1217–1221.
  15. Suzuki M, Suzuki H, Hibi T. Proton pump inhibitors and gastritis. J Clin Biochem Nutr. 2008;42:71–75.
  16. Sipponen P, Price AB. The Sydney System for classification of gastritis 20 years ago. J Gastroenterol Hepatol. 2011;26(Suppl 1):31–34.
  17. Dury S, Nardi J, Gozalo C, Lebargy F, Deslee G. Agranulocytosis Induced by Proton Pump Inhibitors. J Clin Gastroenterol. 2012; 46:859.
  18. Yeo M. Novel action of gastric proton pump inhibitor on suppression of Helicobacter pylori induced angiogenesis. Gut. 2006;55:26–33.
  19. Hagiwara T, Mukaisho K, Nakayama T, Sugihara H, Hattori T. Long-term proton pump inhibitor administration worsens atrophic corpus gastri-tis and promotes adenocarcinoma development in Mongolian gerbils infected with Helicobacter pylori. Gut. 2011;60:624–630.